IC
CNTA

Ikarian Capital’s Centessa Pharmaceuticals CNTA Stock Holding History

Ikarian Capital’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$719K Buy
+18,113
New +$463K 0.06% 117

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Ikarian Capital's CNTA Position: Q1 2026 in Review

Ikarian Capital opened a new position in Centessa Pharmaceuticals (CNTA) in Q1 2026: 18,113 shares worth $719K. The stake represents 0.06% of the portfolio and ranks #117 among its holdings.

161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Ikarian Capital held 18,113 shares of Centessa Pharmaceuticals worth $719K as of Q1 2026.
  • Centessa Pharmaceuticals was a new Ikarian Capital position in Q1 2026.
  • Centessa Pharmaceuticals made up 0.06% of Ikarian Capital's portfolio in Q1 2026, its #117 holding.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.